In this Huberman Lab Essentials episode, my guest is Dr. Matthew Johnson, PhD, a senior researcher for the Center of Excellence for Psilocybin Research and Treatment at Sheppard Pratt’s Institute for Advanced Diagnostics and Therapeutics.
We explore the science and therapeutic potential of psychedelic medicine, including psilocybin, MDMA and LSD. We discuss how these substances can profoundly alter perception and self-identity, providing long-lasting relief from depression, addiction and trauma when used in controlled clinical settings. We also discuss microdosing and emerging research on psychedelics’ potential to support recovery from neurological injuries.
Read the episode show notes at hubermanlab.com.
Thank you to our sponsors
AG1: https://drinkag1.com/huberman
David: https://davidprotein.com/huberman
BetterHelp: https://betterhelp.com/huberman
Timestamps
00:00:00 Matthew Johnson; Psychedelics
00:01:44 Different Classes of Psychedelics
00:04:33 Psychedelics & Altering Models
00:06:18 Sponsor: David
00:07:33 LSD, Psylocibin & Serotonin
00:09:55 Psychedelic Clinical Trials
00:13:40 Therapy, Trust, Psychedelics
00:16:47 Letting Go & Psychedelic Experience, Self-Representation, Lasting Changes
00:22:31 Sponsors: AG1 & BetterHelp
00:25:26 MDMA, Dopamine & Serotonin; Bad Trips & Transcendental Experience
00:28:49 Dangers of Psychedelics
00:31:11 Microdosing Psychedelics, Antidepressant
00:35:27 Head Injuries, Psychedelics, Depression
00:38:29 Acknowledgements
Learn more about your ad choices. Visit megaphone.fm/adchoices
